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1. Introduction 
Seizures can arise as a complication of a number of disease states such as metabolic 
abnormalities, intoxication or withdrawal from drugs, acute trauma, infection; the list is 
exhaustive (Delanty, Vaughan et al. 1998). One of the most common causes of seizures is 
indeed the presence of a brain tumor. Seizures present a preventative, diagnostic and 
management challenge for a number of reasons in this situation. The drugs used for 
treatment may interfere with chemotherapy, may produce untoward cognitive or medical 
side effects, and may not even reach the intended target since the blood brain barrier may be 
pathologic in the abnormal environment of the tumor. The many genetic and pathological 
variations in tumor type may further impact therapies aimed at treating seizures in this 
setting. Further complicating this scenario is the post-operative management of these 
patients, which may occur in an ICU most complex environment. This chapter will review 
contemporary issues in pathophysiology, clinical presentation, complications, treatment, 
and outcomes of seizures associated with brain tumors. 
2. Incidence 
Overall, the incidence of brain tumors is 4% in patients with epilepsy (van Breemen, Wilms 
et al. 2007).  On the other hand, seizures complicate the natural history in 30-70% of patients 
with a primary tumor. (LeBlanc 1974; McKeran 1980; Cascino 1990; Bartolomei 1997). About 
40% of all the patients with metastatic brain tumors will have a seizure during their disease 
(Simonescu 1960; Cohen 1988). Half of these seizures will be simple or partial complex 
seizures and the other half secondary generalized seizures (Ketz 1974; Moots 1995). Some 
tumors, like DNETs and gangliogliomas, with significantly higher seizure frequencies, have 
been associated with intrinsic epileptogenic properties. Among the primary brain tumors, 
the higher incidence of seizures is found in patients with oligodendroglioma (92%) and 
dysembryoplastic neuroectodermal tumors (DNET, 100%) (van Breemen, Wilms et al. 2007). 
Melanoma, choriocarcinoma, lung cancer and breast cancer are tumors frequently 
metastasizing to the brain and associated with hemorrhage and seizures. Among metastatic 
tumors, melanoma seems to have the highest incidence of seizures. Conversely, based on a 
study from the Cleveland Clinic, among patients with intractable chronic epilepsy the most 
common types of tumors discovered are ganglioglioma [in 49/127 (39%) of cases] and low 
grade astrocytoma [in 48/127 (38%) of cases] (Morris 1996). Pleomorphic 
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xanthoastrocytoma, dysembryoplastic neuroectodermal tumors, and oligodendroglioma are 
also tumors frequently associated with chronic epilepsy. Overall, it seems likely that low 
grade, well-differentiated gliomas have higher incidence of seizures than more aggressive 
glioblastomas or anaplastic astrocytomas (Beaumont 2000; van Breemen, Wilms et al. 2007).  
The location of the brain tumor also plays a role in the incidence of seizures, because 
different brain areas are characterized by varying susceptibility to seizures. For example, 
among patients with gliomas, seizures occur in 59% of frontal tumors, 42% of parietal 
tumors, 35% of temporal tumors and 33% of occipital tumors (Scott 1980). Similar 
observations suggest that the limbic and temporal lobe, primary and supplementary motor 
(M-I, M-II) areas, primary and secondary somatosensory (S-I, S-II opercula and insula) areas 
have the lowest thresholds for seizures (Beaumont 2000). In contrast to the other lobes, the 
occipital lobe has a much higher threshold and lower incidence of seizures (Mahaley 1981). 
Tumors in the subcortical areas, such as thalamus and posterior fossa, are much less 
epileptogenic as well. 
3. Pathophysiology of seizures in the context of a brain tumor 
Although the pathogenic mechanism of epileptogenesis in patients with brain tumors has 
not been fully elucidated (Beaumont 2000), it can be traced to the cellular workings and 
intercellular connections within the nervous system. A better understanding of these 
processes may provide new therapeutic targets not just for tumors, but for improved seizure 
control. There are many theories behind the cause of seizures in patients with brain tumors. 
To complicate the matter, different types of tumors may cause seizures through different 
mechanisms.  In the late 1950’s Echlin proposed that brain tumors are cause partial isolation 
and deafferentation of the cerebral cortex, resulting in denervation hypersensitivity (Echlin 
1959). More recent studies have focused on molecular pathobiology and  pathophysiology 
that underlie these lesions and differentiate them from normal tissue. There are differences 
in the ion channel profile between normal glial cell types (Patt 1996). Patt et.al used these 
differences in their study in order to further categorize the properties of 
oligiodendrogliomas and mixed oligiodendrogliomas in eight patients.  Using patch clamp 
techniques, he postulated that oligiodendrogliomas are dominated by action potential 
generating cells (Patt 1996). Sodium channels in tumor cells may play a role in 
epileptogenesis, since these channels are responsible for generating action potentials more 
frequently than others (Patt 1996; Labrakakis 1997). Normal glial cells have a limited 
number of sodium channels. It is not difficult to imagine that a tumor with a mixed cellular 
profile would produce enough sodium channels to allow excitatory circuitry to become the 
dominant player (Beaumont 2000). There are differences in the pathophysiology between 
temporal epilepsy and epilepsy in the temporal lobe secondary to seizure kindling 
(Beaumont 2000). Changes in the extracellular environment, changes in the regulation of 
inhibitory and excitatory amino acids, responses to amino acids, alterations in glial gap 
junctions have all been implicated in epileptogenesis (Beaumont 2000). Tumors that tend to 
cause hemorrhage, necrosis, inflammation and ischemia have a higher incidence of seizures. 
Focal hypoxia, mass effect and edema, altered levels of excitatory amino acids, all have been 
postulated to play a role in epileptogenesis. Derangements in the blood-brain barrier (BBB) 
and its constituents may be another factor that impacts the development and treatment of 
seizures in brain tumors. Although Marchi et. al in their study using acute disruption of the 
blood brain barrier(Marchi, Angelov et al. 2007) did not find that the presence of tumor 
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determined the onset of the seizure in their cohort, BBB disruption may be another 
contribution to an already unstable and pathologic state. The multidrug-resistance gene 
MDR1 (ABCB1, P-glycoprotein) and multidrug-resistance-related protein (MRP, ABCC1) are 
expressed in the cells forming many blood-brain and blood-CSF barriers. These genes and 
proteins contribute to decreased entry of multiple AEDs to the brain parenchyma such as 
phenytoin, carbamazepine, phenobarbital, lamotrigine and felbamate. These proteins are 
over-expressed in the cells of patients with glioma (Calatozzolo, Gelati et al. 2005), focal 
cortical dysplasia and ganglioglioma (Aronica, Gorter et al. 2003). The genetic characteristics 
of the tumor play a substantial role in their treatment, thereby impacting the treatment of 
seizures too. Loci 1p and 19q have been implicated in the prognosis of oligiodendrogliomas 
in a number of studies. (Hata, Shono et al. 2007; Ramirez, Bowman et al. 2010). Despite the 
advances in research in these key areas of molecular biology, genetics and ion channel 
function, estimating the individual’s susceptibility to the above alterations is still an elusive 
target. 
In addition to primary brain neoplasms, systemic cancer can metastasize to the brain and 
produce seizures as their first manifestation. The intracranial metastases usually originate 
from embolization of neoplastic cells to the brain, commonly in terminal arterial supply 
territories, such as the gray white matter junction. Systemic cancer may induce seizures 
through additional non-invasive mechanisms: coagulopathy and stroke (sinus thrombosis), 
non-bacterial thrombotic endocarditis with cerebral emboli, systemic metabolic 
derangements, such as hypomagnesemia (van de Loosdrecht, Gietema et al. 2000) or 
hyponatremia (McDonald and Dubose 1993), opportunistic infections after chemotherapy or 
direct toxicity of chemotherapeutic agents to the brain (Meropol, Creaven et al. 1995; 
Delanty, Vaughan et al. 1998). Paraneoplastic syndromes, such as limbic encephalopathy 
with anti Hu antibodies can be associated with seizures preceding the diagnosis of cancer 
(Dalmau, Graus et al. 1992). EEG or continuous video-EEG may be necessary to evaluate 
these patients and reach the correct diagnosis (Figure 1).  
4. Clinical presentation 
Seizures are one of the most common presentations in patients with brain tumors. A first, 
unprovoked seizure in an adult is always suggestive of an intracranial tumor, until proven 
otherwise (Ropper 2009). As a sign, seizures may accompany other vague, non-localizing 
symptoms such as apathy, irritability, altered mental status, dizziness (Ropper 2009), as well 
as signs of increased intracranial pressure, such as diplopia, nausea, headache and 
decreased visual acuity. 
Several seizure types have been reported and mainly reflect the location of the lesion. 
Parasagittal meningiomas may present with generalized seizures when located in the 
anterior one third of the sagittal sinus, whereas meningiomas of the middle third usually 
present with focal seizures, at times following a Jacksonian marching pattern. Simple or 
partial seizures characterized by olfactory, gustatory and epigastric auras, 
depersonalization, feelings of fear or pleasure, are usually an indication of temporal lobe 
pathology. Complex partial seizures with repetitive psychomotor movements, impairment 
of consciousness or déjà-vu phenomena are also associated with the temporal lobe. 
Delusions and psychotic behaviour have been reported with frontal lobe tumors (Sato, 
Takeichi et al. 1993). Lesions involving the frontal eye fields are associated with turning of 
the eyes and head to one side (contraversive or ipsiversive, depending on the side of turning 
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compared to the lesion and the timing of the observation, ie ictal vs interictal). Parietal lobe 
tumors are associated with sensory seizures and occipital lobe tumors can cause seizures 
with lights, colors, and geometric patterns (Ropper 2009). Even non-neoplastic mass lesions 
may have seizures as a part of their clinical presentation. The classic example is gelastic 
seizures in hypothalamic hamartomas (Addas, Sherman et al. 2008; Striano, Striano et al. 
2009).  
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Fig. 1. 57 year old woman, history of multiple resections of reccuren right frontal 
meningioma, with altered mental status, in non-convulsive status epilepticus. The seizures 
were treated successfully with multiple anti-epileptic medications including a midazolam 
drip. (a) CT brain without contrast, evidence of encephalomalacia in the resection cavity 
with increased edema. (b) start of ictal activity in the frontal derivations (F2, F4, F8) 
consistent with the region of the prior meningioma resection (c) evolution of the ictal 
activity into non-convulsive status epilepticus (d) end of ictal activity. 
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4.1 Status epilepticus 
Status epilepticus (SE) can also occur in patients with brain tumors, either convulsive or 
non-convulsive. In a recent study from the University of Virginia, 555 patients were 
admitted with a diagnosis of SE over a 7-year period. Fifty patients had a concurrent 
diagnosis of cancer, 28 (5%) of whom had SE related to the tumor or its treatment 
(Cavaliere, Farace et al. 2006).  SE occurs either at the time of tumor diagnosis (29%) or 
during tumor progression (23%). However, an almost equal percentage of SE occurred 
while the tumor was stable (23%) in a recent study (Cavaliere, Farace et al. 2006). Because 
some tumors present with non-convulsive seizures or non-convulsive status epilepticus 
(NCSE), a clinical presentation of decreased or altered mental status, should not be 
primarily attributed to the tumor. An evaluation with EEG should be undertaken to 
exclude NCSE, that may be amenable to treatment.  Drislane reported 6 patients with 
systemic cancer, whose EEGs showed NCSE. Three patients were confused, and the other 
three were stuporous or comatose. The possibility of paraneoplastic encephalopathy was 
raised in 3 of them. Antiepileptic treatment led to an improved mental status in four of 
these patients (Drislane 1994). Five patients out of 84 (6%) with cancer and altered mental 
status (coma or delirium) were found to be on NCSE by EEG in another study from Italy. 
None of these patients had brain metastases: one was aphasic, 2 patients treated with 
ifosfamide had absence and 2 patients treated with cisplatin complex partial status 
epilepticus. All had rapid recovery after antiepileptic treatment (Cocito, Audenino et al. 
2001). In a recent study, four patients never diagnosed before with metastatic CNS disease 
presented with altered mental status. All patients had abnormal neuroimaging of the 
brain, were in NCSE by EEG and were treated with fosphenytoin IV. In 2 patients the 
NCSE resolved, but in the other two, despite an initial mental status improvement, status 
recurred and both eventually died after 5 and 20 days, respectively (Blitshteyn and Jaeckle 
2006).  
5. Diagnosis 
In most cases, seizures can be easily diagnosed, if they present as convulsions. However, 
other paroxysmal or repetitive movements can occur in patients with intracranial 
pathology, such as extrapyramidal tremor, clonus, blepharospasm, fasciculations, 
shivering or posturing and occasionally this may lead to confusion, especially if a 
physician or nurse is not present during their occurrence. On the other hand, many 
epileptic phenomena are non-convulsive and can present with a pleiade of symptoms 
and signs, including confusion, blank starring, fugue, subtle (and frequently 
unnoticeable) twitching of the face or eyelids or nystagmus. The routine 
electroencephalogram may not catch any of these events or may be compromised by 
movement artifacts. In this case of uncertainty, we recommend a continuous video-EEG 
monitoring lasting for few hours to a day. If the events are recorded and are not epileptic 
in nature, then the test should be discontinued, otherwise should be extended until a 
conclusion is reached. 
Neuroimaging is also paramount, especially in cases of refractory seizures, to exclude 
additional pathology than the tumor per se (new bleed, infarction, sinus thrombosis or 
infection, which can occur in patients undergoing chemotherapy or radiation). A magnetic 
resonance imaging is considered a better test than computed tomography, since it can reveal 
smaller anatomical details and differentiate faster between a new stroke vs paralysis due to 
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Todd’s phenomenon. If the patient is actively having seizures or SE, the diffusion-weighted 
imaging sequence can reveal restricted diffusion in the cortical mantle, where the seizures 
emanate from. Lastly, a lumbar puncture, performed if there are no signs of hydrocephalus 
or midline shift, can also infrequently contribute to the diagnosis, by revealing 
leptomeningeal extension of the tumor, measuring the opening pressure or identifying an 
infectious agent. 
6. Treatment - Issues in management 
6.1 Use of anti-epileptic medications 
There are several important details regarding the management of these complex patients. 
One main theme is the understanding that surgical management supersedes medical 
management. Studies have shown that resection of the epileptogenic zone due to brain 
tumors may lead to seizure freedom or significant control of seizures in 70-90% of patients 
(Britton, Cascino et al. 1994; Zentner, Hufnagel et al. 1997).  
Medication interactions are a very important problem and can lead to difficulties in 
compliance, tolerance and side effects. Most patients are on a regimen of antiepileptic drugs 
(AEDs), radiation therapy and chemotherapy. Antiepileptics, especially those affecting the 
cytochrome P450 system, may affect the metabolism of chemotherapeutic agents. These 
agents have a narrow therapeutic window and real potential for toxicity or lethal side 
effects. Usually, the addition of phenytoin, carbamazepine, phenobarbital and other 
inducers, reduces the levels or efficacy of cyclophosphamide, methotrexate, adriamycin, 
nitrosoureas, paclitaxel, etoposide, topotecan, irinotecan, thiotepa and corticosteroids 
(Glantz, Cole et al. 2000; Patsalos, Froscher et al. 2002). Valproic acid, being an inhibitor, can 
have the opposite effect and increase the chemotherapeutic agents’ levels. In addition, 
competition for binding to plasma proteins may be important with several of those 
medications. Choosing an appropriate anti-epileptic for patients with brain tumors involves 
more than adequate control of seizures. The appropriate use of certain AEDs can alleviate 
other symptoms of brain neoplasm, including pain, depression, anxiety, and weight gain. 
Because of their intrinsic mechanism of action, AED may be uniquely qualified to address 
these additional symptoms. There are multiple studies in both the Psychiatric and 
Neuroncology literature to support the use of AEDs for symptoms related to depression, 
anxiety, and pain (Thompson, Takeshita et al. 2006).   
An interesting aspect of the antiepileptic drug use in patients with cancer is their potential 
for antineoplastic or immunosuppressive effect (Bardana, Gabourel et al. 1983; Kikuchi, 
McCormick et al. 1984; Blaheta and Cinatl 2002). Valproate exhibits inherent antitumor 
activity through inhibition of histone deacetylase. In the treatment of medulloblastoma in 
children, Li et. al concluded that valproic acid possesses potent in vitro and in vivo 
antimedulloblastoma activities correlating with induction of histone hyperacetylation and 
regulation of pathways critical for maintaining growth inhibition and cell cycle arrest (Li, 
Shu et al. 2005). Pregabalin, a newer agent was found in a small study to be effective as 
monotherapy, encouraging the study authors to do a larger prospective study (Novy, Stupp 
et al. 2009). Gabapentin in another small study was postulated to interact with a leucine 
binding site to reduce seizures in a group of 14 patients (Perry and Sawka 1996).Anti-
epileptic medications, and their many applications, are a unique area of further research in 
the world of brain tumors. This is an area where individualized treatment is of paramount 
importance. One should take into account the histopathology of the tumor, the location of 
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the mass, the presence of pre-existing epilepsy, the extent of additional injury incurred by 
craniotomy, the involvement of other important organs metabolizing the drugs, the 
nutritional state of the patient, the pharmacological interactions between the agents and the 
ability of the patient to tolerate side effects of the treatment.  
6.2 Side effects of antiepileptic medications 
The adverse interactions between AEDs and chemotherapy are often related to enzyme 
induction by the former (Pursche, Schleyer et al. 2008). Major offenders include 
carbamazepine, phenytoin, phenobarbital, primidone, and valproic acid (Ruggiero, Rizzo et 
al. 2010). Interaction between antiepileptics and irradiation treatment offered to the brain or 
spine may lead to dermatologic complications. Skin rash in patients treated with phenytoin 
and brain irradiation may herald Stevens-Johnson syndrome (Cockey, Amann et al. 1996; 
Eralp, Aydiner et al. 2001). One retrospective study, however, of 289 patients with brain 
tumors treated with antiepileptics and radiation found only one (0.3%) patient who 
developed erythema multiforme. Phenytoin was associated with milder rashes in 22% of 
patients, a higher incidence than the usual 5-10%. These rashes did not appear to have a 
temporal relation to radiation, because they usually occurred before its initiation (Mamon, 
Wen et al. 1999). Valproic acid has been implicated in Rowell’s syndrome - lupus 
erythematosus associated with erythema multiforme-like lesions (Esteve, Favre et al. 2002). 
6.3 Prophylactic treatment with antiepileptic medications 
The issue of prophylactic treatment of patients with brain tumors is very complex. If a 
seizure has already occurred, there is little doubt for the value of antiepileptics (Glantz, Cole 
et al. 2000), but when the patient has never exhibited epileptic phenomena, such a treatment 
becomes more controversial. Efficacy of the treatment has to be balanced with adverse 
events associated with the chosen drugs. Despite the best efforts, a significant percentage of 
patients still have breakthrough seizures and the response to the treatment is very 
unpredictable. Several reasons have to be considered: (1) inability of the AED to address or 
correct the vast range of physiologic derangements induced by brain tumors, (2) difficulty 
maintaining appropriate antiepileptic levels and (Lee, Wen et al.) tumor progression or 
recurrence (Beaumont 2000; Schaller and Ruegg 2003). Therefore, it is not surprising that 
there is conflicting literature regarding the use of anticonvulsants in this clinical setting.  The 
design of the study (prospective or retrospective, randomized and blinded or not), the 
uniformity of the tumors studied (AEDs against a certain type of tumor or against tumors of 
various pathologies and locations), the drugs used (older or newer AEDs), the comparison 
arm (placebo vs another AED), the dose utilized (with or without a loading dose, based on 
ideal or unadjusted patient weight), the timing of the administration (pre-, intra- or 
postoperatively), the adjustment of the dose based on AED levels (total or free, depending 
on levels of albumin and their binding to it), the concurrent administration of other 
medications that can affect the AED levels (such as chemotherapy or steroids), all these are 
factors that play a role in the results and conclusions and contribute to the confusion. Early 
studies were in agreement that prophylaxis against seizure was very important. In the 80’s, 
Kvam et al. from Columbia Presbyterian Hospital in New York, reported only 5 patients 
having preoperative seizures out of 538 who underwent craniotomy. The authors suggested 
a preoperative loading dose of 10mg/kg of phenytoin, followed by a postoperative dose of 
5mg/kg/day (Kvam 1983). In a double-blind, randomized study of phenytoin (100 mg tid) 
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vs placebo in 281 post-craniotomy patients, the phenytoin group had significantly less 
seizures (12.9% vs 18.4%) and highest protection was present between days 7 and 72. 
Routine prophylaxis with phenytoin (in a dosage of 5 to 6 mg/kg/day) was recommended 
by the authors in high-risk patients post craniotomy. They also recommended that treatment 
should be started 1 week preoperatively and therapeutic levels of phenytoin should be 
maintained (North, Penhall et al. 1983). In another study, 374 patients post-craniotomy were 
randomized to receive phenytoin (15 mg/kg IV during surgery, followed by 3-6 
mg/kg/day for 3 days) or placebo (Lee 1989). The group receiving phenytoin had two early 
postoperative seizures and the placebo nine, but the difference was not statistically 
significant. Eighty percent of the seizures occurred within twenty minutes after surgery. 
Thus, the authors recommended that prophylactic anticonvulsant medication be given at 
least 20 minutes before completion of wound closure. In a subsequent Italian study, 65/128 
(51%) patients with supratentorial brain tumors had preoperative seizures and were treated 
with antiepileptic drugs. Those without preoperative seizures, were randomized to receive 
phenobarbital or phenytoin as prophylactic treatment or no treatment. No significant 
difference in seizure incidence was found between patients treated (7%) and those not 
treated (18%). The authors suggested short-term preventive antiepileptic treatment after 
surgery in patients without preoperative seizures and continuation of postoperative 
treatment in patients with preoperative epilepsy (Franceschetti, Binelli et al. 1990). This view 
was not shared by the authors of a subsequent large study, who did not recommend 
prophylactic antiepileptics after supratentorial craniotomy. In this study, 276 post-
craniotomy patients were randomized to receive carbamazepine or phenytoin for six or 24 
months, or no treatment (Foy, Chadwick et al. 1992). The three treatment groups did not 
overall differ in the risk of seizures, but there was a non-significant 10% reduction of 
seizures in the two groups which received antiepileptic medications. Meningiomas had the 
highest risk for seizures (75% by 4 years) and pituitary tumors the lowest (21% by 4 years). 
Longer operations, those associated with dissection of the lesion away from the surface of 
the brain and left-sided or bilateral lesions also carried a higher risk. Early seizures (within 
one week) after craniotomy did not increase the likelihood of late epilepsy. Based on these 
data, prophylactic anticonvulsants could not be recommended by the authors routinely 
following supratentorial craniotomy. Additional conflicting data comes from the results of a 
prospective, stratified, randomised, double-blind Dutch study, comparing 300 mg 
phenytoin/day to 1500 mg valproate/day given for 1 year in one hundred post craniotomy 
patients. Fourteen patients had postoperative seizures, but there was no difference in 
seizure incidence between the two groups (Beenen, Lindeboom et al. 1999). Finally, a meta-
analysis of six controlled studies addressing the issue showed a tendency of prophylactic 
antiepileptics to prevent postoperative convulsions in patients without pre-existing seizures, 
but this effect did not reach statistical significance.(Kuijlen, Teernstra et al. 1996).  
There are also studies looking at anti-epileptics other than phenytoin. Glantz et al. 
conducted a well designed randomized, double-blind, placebo-controlled study 
comparing the incidence of first seizures in 74 valproate and placebo-treated patients with 
newly diagnosed supratentorial brain tumors. The drug and placebo groups did not differ 
significantly in the incidence of seizures [35% in the valproate and 24% in the placebo 
treated group (odds ratio 1.7, 95% CI 0.6-4.6, p = 0.3)]. Based on these results no 
prophylactic treatment with valproate could be recommended (Glantz, Cole et al. 1996).  
In a large retrospective analysis of 195 patients with metastatic brain tumors, Cohen et al. 
reported that 18% of patients presented with seizures. Of the remaining seizure-free 
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patients, 40% were treated prophylactically with antiepileptics (phenytoin in > 90%). In a 
follow-up period of up to 59 weeks, 10% of patients developed late seizures. The 
incidence of seizures did not differ between treated (13.1%) and untreated (11.1%) groups. 
However, this study is flawed by the fact that two third of patients with seizures had sub-
therapeutic antiepileptic levels. The authors did not advocate antiepileptic use, unless the 
patient has the first seizure (Cohen 1988). More recently, a meta-analysis evaluated 5 trials 
with the following  inclusion criteria: (1) patients with a neoplasm,  (2) either primary 
glial tumors, cerebral metastases or meningiomas, (3) no history of epilepsy. These 
patients were randomized to either an antiepileptic drug or placebo. The three 
antiepileptics studied were phenobarbital, phenytoin, and valproic acid.  This meta-
analysis confirmed the lack of antiepileptic benefit at one week and at six months of 
follow-up. In addition, the antiepileptics had no effect on seizure prevention for specific 
tumor pathology (Sirven, 2004 #83). Moreover, there is growing evidence supporting 
increased frequency and severity of side effects from antiepileptics in this population: in a 
meta-analysis of studies examining prophylactic treatment in patients with newly 
diagnosed brain tumors, 23.8% (range 5-38%) of treated patients experienced side-effects 
that were severe enough to lead to change or discontinuation of the medications. This 
incidence is higher than that in the general population and should make physicians 
skeptical regarding use in this setting (Glantz, Cole et al. 2000).  
Other important factors frequently playing a role are personal preference, previous 
training or experience in the decision to prescribe anti-epileptic medications. According 
to a study conducted in Rhode Island, 55% of participating physicians gave antiepileptic 
prophylaxis, but the percentage differed according to the subspecialty: 33% of radiation 
oncologists, 50% of oncologists, 53% of neurologists and 81% of neurosurgeons (Glantz, 
Cole et al. 1996; Glantz, Cole et al. 2000).  One of the most authoritative reports on this 
subject is the Quality Standards Subcommittee of the American Academy of Neurology, 
who published a meta-analysis of 12 studies, which had addressed the issue of 
prophylactic antiepileptic treatment for newly diagnosed brain tumor patients. Four 
were randomized and 8 were cohorts. Only one study showed significant difference 
between treated and untreated groups and, actually, favored the untreated. The overall 
odds ratio from the randomized trials was 1.09, 95% CI 0.63—1.89 (P = 0.8) for seizure 
incidence and 1.03, 0.74-1.44 (P = 0.9) for seizure-free survival. Therefore, the 
Subcommittee recommended no prophylactic use of antiepileptics on patients with 
newly diagnosed brain tumors. Although not excluding the possibility that some 
subgroups of brain tumor patients may be at a higher risk for seizures (melanoma, 
hemorrhagic or multiple metastatic lesions, tumors located near the Rolandic fissure, 
slow-growing primary CNS tumors), the Subcommittee did not find any reason for 
prophylaxis in those patients (Glantz, Cole et al. 2000). In the contemporary literature, 
there are still no concrete answers. A recent review(Kargiotis, Markoula et al. 2011) 
recommend that short-term anticonvulsant prophylaxis after surgical excision since they 
found that up to 13% of the patients may experience seizures within the first 
postoperative week, irrespective of the presence of preoperative seizure history or not. 
Alternatively guidelines from the American Association of Neurological Surgeons 
(AANS) and the Congress of Neurological Surgeons (CNS) do not recommend the 
prophylactic use of antiepileptic drugs to prevent seizures in brain metastases 
(Mikkelsen, Paleologos et al. 2010).   
www.intechopen.com
  
Management of CNS Tumors 
 
420 
7. Post-operative complications 
Seizures may present at two distinct periods of time in the course of the disease. They can 
present as one of the initial symptoms or later in the course of the disease during 
chemotherapy or after surgical intervention (Kargiotis, Markoula et al. 2011). What is the 
current risk of postoperative seizures in patients with neoplasm? There are no current 
prospective trials looking at this issue. In the aforementioned study by Kvam et al., 538 
patients underwent elective craniotomy. Only 23 of these patients had a post operative 
seizure. They concluded that in this case-series, the most common risk factor for post-
operative seizure was inadequate anticonvulsant prophylaxis. Patients in this series were 
also noted to have serum sodium level less than 130, which may have played a role in 
reducing the seizure threshold and is not uncommon in postoperative neurosurgical 
patients (Kvam 1983).  In a case series by Fukamachi, risk factors for post-operative seizures 
included pre-operative seizures, sites of the lesion, and subtherapeutic anti-convulsants 
(Fukamachi 1985). In more contemporary studies post-operative seizures are reported in 
complications for new techniques (Kassam, Engh et al. 2009), and seizure rates 
retrospectively in specific tumor types (Lwu, Hamilton et al. 2010). Surgical approaches can 
also determine the risk of post-operative seizures. In a study conducted in Mayo clinic, 
Milligan et. al, retrospectively analyzed 197 patients comparing transcallosal approach to a 
transcortical approach for resection of an intraventricular lesion. They found that patients 
undergoing the transcallosal approach had a 4.4 fold increase in the risk of seizure (Milligan 
and Meyer 2010). 
Seizures may also compromise the airway, cause limb injuries or structural brain injury, 
possibly predisposing the patient to more seizures or even status epilepticus (Deutschman 
1985). Seizures can also cause cerebral acidosis, cerebral edema and further elevations of the 
intracranial pressure (which may already be elevated), all of them challenging the 
compensatory mechanisms of the brain (Lee 1989). Metabolic disturbances, such as 
hyponatremia or hypernatremia, hypoxia, pain-induced hyperventilation and 
hyperglycemia that are frequently noted postoperatively may also contribute to increased 
seizure frequency and should be treated aggressively. 
8. Outcomes 
Against easy assumptions, there is data supporting a better outcome in patients with brain 
tumors and seizures (Beaumont 2000). Despite complicating the course of the disease process 
in a brain neoplasm, seizures are actually among the factors that may improve patient 
outcome (Chandana, Movva et al. 2008), although this view may not be shared by all experts. 
In a retrospective analysis of 560 patients with primary supratentorial tumors, the median 
survival of the 164 (29%) patients presenting with epilepsy was 37 months compared to 6 
months of  those presenting with other symptoms (P < 0.0001) (Smith, Hutton et al. 1991). In 
the study by Whittle and Beaumont of 34 supratentorial oligodendrogliomas, 17% of patients 
who presented with seizures and 67% of those who presented with other symptoms had died 
in the follow-up. However, in a multivariate model, young age and not epilepsy was a 
favorable independent predictor (Whittle 1995). In a recent study of 35 patients with SE, 8 
(23%) died within 30 days after the status. More patients with systemic cancer (50%) than with 
primary brain tumors (14%) died within 30 days, implying that the tumor histology is a more 
important factor for mortality than SE (Cavaliere, Farace et al. 2006). 
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9. Conclusions 
Anti-epileptic medications, and their many applications, are a unique area of further 
research in the world of brain tumors. This is an area where individualized treatment is of 
paramount importance. One should take into account the histopathology of the tumor, the 
location of the mass, the presence of pre-existing epilepsy, the extent of additional injury 
incurred by craniotomy, the involvement of other important organs metabolizing the drugs, 
the nutritional state of the patient, the pharmacological interactions between the agents and 
the ability of the patient to tolerate side effects of the treatment. Future areas of research 
include pain control, synergistic interplay between anti-epileptics and chemotherapeutic 
agents, and mood stabilization.  
10. Abbreviations 
DNET - dysembryoplastic neuroepithelial/neuroectodermal Tumor 
MDR – multi-drug resistant 
AED – anti-epileptic drug 
EEG - Electroencephalogram 
SE – status epilepticus 
NCSE – non-convulsive status epilepticus 
CNS – central nervous system 
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